Worldwide Quality Control Set to Tame Biomarker Variation
This is a story about how differences among individual centers’ CSF Aβ and tau measurements are posing a serious problem...
589 RESULTS
Sort By:
This is a story about how differences among individual centers’ CSF Aβ and tau measurements are posing a serious problem...
Biomarkers stand poised to transform Alzheimer’s research, but scientists first must iron out pesky technical issues and ensure that markers give reliable, repeatable results...
At the Alzheimer’s Association International Conference, two companies presented their progress toward oligomer-measuring assays...
When it comes to CSF Aβ and tau measurements, pharma companies developing Alzheimer’s disease treatments and diagnosing clinicians share similar goals...
For cerebrospinal fluid tests of Alzheimer’s biomarkers, the time has come to grow up...
In an ideal future, physicians would diagnose people with incipient Alzheimer’s disease long before memory problems appear...
Researchers with eyes peeled toward prodromal AD probably see the diagram of the field’s five most validated markers in their sleep...
Women run a higher risk of getting Alzheimer’s disease than do men, yet surprisingly little is known about how gender interacts with the disease or affects the brain...
Researchers are trying to tackle whether and how to disclose genetic and biomarker data to people in both routine clinical care and research settings...
A healthy brain switches between its different functional networks like a well-oiled machine, but as dementia takes over, communication becomes disorganized...
At the 7th Leonard Berg Symposium, brain imaging researchers of various stripes took stock of what brain imaging tells the field about the preclinical period of Alzheimer disease...
Data from the DIAN paint a sobering picture, showing that a cascade of pathophysiological changes begins decades before a person is likely to develop familial AD...
Merck announced this week that it has begun enrolling for the largest clinical trial of a β-secretase (BACE1) inhibitor in Alzheimer’s disease patients...
The longest study yet to correlate AD biomarkers in CSF with disease progression confirms that β amyloid levels bottom out up to 10 years before the clinical onset of disease...
Individual labs are experimenting trying to improve the differential diagnoses of related dementias...